Eurofins Viacor BioPharma Services to Relocate to New Facility in Lenexa, KS

Eurofins Viracor BioPharma Services, a provider of analytical testing and clinical trial services, is moving its headquarters and laboratory operations to a new, custom-built 96,000 sq. ft. facility in Lenexa, Kansas, scheduled for completion in September 2025.

This strategic move, although only a few miles from its previous location, marks a milestone in the company’s continued growth and commitment to delivering solutions to the biopharmaceutical industry.

Eurofins Viracor BioPharma Services was formally spun out of Eurofins Viracor in 2020 to focus exclusively on supporting biopharmaceutical sponsors with specialized analytical and clinical trial services. Previously, both companies operated from the same facility, but with Eurofins Viracor BioPharma’s relocation to a new, dedicated space, each organization can better concentrate on its core market—Eurofins Viracor on clinical diagnostics and Eurofins Viracor BioPharma on biopharma services. This separation allows both to take full advantage of the strategic benefits offered by the Kansas City region, including access to top-tier scientific talent, centralized logistics, and a life sciences ecosystem that fosters innovation and growth.

The new facility supports the increasing demand for advanced testing services, particularly in the areas of sequencing and precision medicine, cell-based assays, high-complexity flow cytometry, vaccine development and biomarker analysis.

Eurofins Viracor BioPharma’s expanded infrastructure will also enhance its ability to support custom assay development, GLP/GCLP-compliant assay validation, and clinical sample testing across all phases of drug development as well as provide space for new service line launches in the future. The facility will house analytical platforms, integrated automation systems, and expanded biorepository capacity, enabling faster turnaround times, increased throughput, and improved data integrity.